|
CZ20032990A3
(cs)
*
|
2001-05-05 |
2004-04-14 |
Smithkline Beecham P. L. C. |
N-aroylové cyklické aminy
|
|
GB0115862D0
(en)
*
|
2001-06-28 |
2001-08-22 |
Smithkline Beecham Plc |
Compounds
|
|
GB0124463D0
(en)
|
2001-10-11 |
2001-12-05 |
Smithkline Beecham Plc |
Compounds
|
|
GB0127145D0
(en)
*
|
2001-11-10 |
2002-01-02 |
Smithkline Beecham |
Compounds
|
|
GB0130335D0
(en)
*
|
2001-12-19 |
2002-02-06 |
Smithkline Beecham Plc |
Compounds
|
|
MXPA04002269A
(es)
|
2002-07-09 |
2004-06-29 |
Actelion Pharmaceuticals Ltd |
Derivados de 7,8,9,10-tetrahidro-6h-azepino,6,7,8,9-tetrahidro-pirido y 2,3-dihidro-2h-pirrolo[2,1-b]-quinazolinona.
|
|
WO2004026866A1
(en)
*
|
2002-09-18 |
2004-04-01 |
Glaxo Group Limited |
N-aroyl cyclic amines as orexin receptor antagonists
|
|
BR0315115A
(pt)
|
2002-10-11 |
2005-08-16 |
Actelion Pharmaceuticals Ltd |
Compostos, composições farmacêuticas, método para tratar ou prevenir doenças ou distúrbios em que se requer um antagonista de receptores de orexina humana, processo para a fabricação de composições farmacêuticas, e, uso de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
|
|
GB0225938D0
(en)
*
|
2002-11-06 |
2002-12-11 |
Glaxo Group Ltd |
Novel compounds
|
|
GB0225944D0
(en)
*
|
2002-11-06 |
2002-12-11 |
Glaxo Group Ltd |
Novel compounds
|
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
|
ES2297413T3
(es)
|
2003-04-28 |
2008-05-01 |
Actelion Pharmaceuticals Ltd. |
Derivados de quinoxalinona-3-ona utilizados como antagonistas del receptor de orexina.
|
|
JP4094050B2
(ja)
|
2004-03-01 |
2008-06-04 |
アクテリオン ファーマシューティカルズ リミテッド |
置換１，２，３，４−テトラヒドロイソキノリン誘導体
|
|
US20080125403A1
(en)
|
2004-04-02 |
2008-05-29 |
Merck & Co., Inc. |
Method of Treating Men with Metabolic and Anthropometric Disorders
|
|
WO2006081522A2
(en)
*
|
2005-01-26 |
2006-08-03 |
The Regents Of The Unversity Of California |
Modulation of nmda receptor currents via orexin receptor and/or crf receptor
|
|
US7501395B2
(en)
|
2005-04-25 |
2009-03-10 |
Eisai R & D Management Co., Ltd. |
Method of screening for antianxiety drugs
|
|
US20080267888A1
(en)
*
|
2005-05-26 |
2008-10-30 |
Pandey Surendrakumar Satyanara |
Heterocyclic Derivatives
|
|
AU2007254179B2
(en)
*
|
2006-05-18 |
2013-03-21 |
Pharmacyclics Llc |
Intracellular kinase inhibitors
|
|
EP2049110B1
(en)
|
2006-07-14 |
2014-08-20 |
Merck Sharp & Dohme Corp. |
Bridged diazepan orexin receptor antagonists
|
|
CL2007002809A1
(es)
*
|
2006-09-29 |
2008-04-18 |
Actelion Pharmaceuticals Ltd |
Compuestos derivados de 3-aza biciclo [3.1.0]hexano; y su uso en el tratamiento de enfermedades tales como desordenes psicoticos y de ansiedad, desordenes del sueno, uso y abuso de sustancias psicoactivas, demencia y deterioro de funciones cognitivas
|
|
US8133901B2
(en)
|
2006-12-01 |
2012-03-13 |
Actelion Pharmaceuticals Ltd. |
3-heteroaryl (amino or amido)-1-(biphenyl or phenylthiazolyl) carbonylpiperidine derivatives as orexin receptor inhibitors
|
|
PE20081229A1
(es)
|
2006-12-01 |
2008-08-28 |
Merck & Co Inc |
Antagonistas de receptor de orexina de diazepam sustituido
|
|
TW200833328A
(en)
|
2006-12-28 |
2008-08-16 |
Actelion Pharmaceuticals Ltd |
2-aza-bicyclo[3.1.0]hexane derivatives
|
|
CL2008000836A1
(es)
*
|
2007-03-26 |
2008-11-07 |
Actelion Pharmaceuticals Ltd |
Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras.
|
|
JP2010527924A
(ja)
|
2007-05-18 |
2010-08-19 |
メルク・シャープ・エンド・ドーム・コーポレイション |
オキソ架橋ジアゼパンオレキシン受容体アンタゴニスト
|
|
US8030495B2
(en)
|
2007-05-23 |
2011-10-04 |
Coleman Paul J |
Cyclopropyl pyrrolidine orexin receptor antagonists
|
|
WO2008147518A1
(en)
*
|
2007-05-23 |
2008-12-04 |
Merck & Co., Inc. |
Pyridyl piperidine orexin receptor antagonists
|
|
MX2009013293A
(es)
|
2007-06-04 |
2010-02-15 |
Synergy Pharmaceuticals Inc |
Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
|
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
|
JP2010531871A
(ja)
*
|
2007-07-03 |
2010-09-30 |
アクテリオン ファーマシューティカルズ リミテッド |
３−アザ−ビシクロ［３．３．０］オクタン化合物
|
|
KR20100046047A
(ko)
*
|
2007-07-27 |
2010-05-04 |
액테리온 파마슈티칼 리미티드 |
2-아자-비시클로[3.3.0]옥탄 유도체
|
|
AR067665A1
(es)
|
2007-07-27 |
2009-10-21 |
Actelion Pharmaceuticals Ltd |
Derivados de trans-3- aza-biciclo ( 3.1.0) hexano
|
|
CA2699328A1
(en)
*
|
2007-09-24 |
2009-04-02 |
Actelion Pharmaceuticals Ltd |
Pyrrolidines and piperidines as orexin receptor antagonists
|
|
BRPI0908096A2
(pt)
|
2008-02-21 |
2015-08-25 |
Actelion Pharmaceuticals Ltd |
Derivado de 2-aza-biciclo [2.2.1] heptano
|
|
CN102015645B
(zh)
*
|
2008-04-30 |
2012-11-14 |
埃科特莱茵药品有限公司 |
哌啶和吡咯烷化合物
|
|
EP2810951B1
(en)
|
2008-06-04 |
2017-03-15 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
CA2729985A1
(en)
*
|
2008-07-07 |
2010-01-14 |
Actelion Pharmaceuticals Ltd |
Thiazolidine compounds as orexin receptor antagonists
|
|
CA2730603C
(en)
|
2008-07-16 |
2019-09-24 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
EP2348857B1
(en)
|
2008-10-22 |
2016-02-24 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
|
JP5557845B2
(ja)
|
2008-10-31 |
2014-07-23 |
メルク・シャープ・アンド・ドーム・コーポレーション |
糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
|
|
TW201031407A
(en)
|
2008-12-02 |
2010-09-01 |
Glaxo Group Ltd |
Novel compounds
|
|
GB0823467D0
(en)
|
2008-12-23 |
2009-01-28 |
Glaxo Group Ltd |
Novel Compounds
|
|
US20120040991A1
(en)
|
2009-04-24 |
2012-02-16 |
Glaxo Group Limited |
3-azabicyclo [4.1.0] heptanes used as orexin antagonists
|
|
WO2011023585A1
(en)
|
2009-08-24 |
2011-03-03 |
Glaxo Group Limited |
Piperidine derivatives used as orexin antagonists
|
|
US20120149723A1
(en)
|
2009-08-24 |
2012-06-14 |
Romano Di Fabio |
5-methyl-piperidine derivatives as orexin receptor antagonists for the treatment of sleep disorder
|
|
AU2011218830B2
(en)
|
2010-02-25 |
2014-07-24 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
|
WO2012089606A1
(en)
|
2010-12-28 |
2012-07-05 |
Glaxo Group Limited |
Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists
|
|
WO2012089607A1
(en)
|
2010-12-28 |
2012-07-05 |
Glaxo Group Limited |
Novel compounds with a 3a-azabicyclo [4.1.0] heptane core acting on orexin receptors
|
|
MX348131B
(es)
|
2011-02-25 |
2017-05-26 |
Merck Sharp & Dohme |
Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos.
|
|
AR088352A1
(es)
|
2011-10-19 |
2014-05-28 |
Merck Sharp & Dohme |
Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
|
|
WO2013119639A1
(en)
|
2012-02-07 |
2013-08-15 |
Eolas Therapeutics, Inc. |
Substituted prolines / piperidines as orexin receptor antagonists
|
|
US9440982B2
(en)
|
2012-02-07 |
2016-09-13 |
Eolas Therapeutics, Inc. |
Substituted prolines/piperidines as orexin receptor antagonists
|
|
TWI570120B
(zh)
|
2012-06-04 |
2017-02-11 |
艾克泰聯製藥有限公司 |
苯并咪唑脯胺酸衍生物
|
|
WO2014022528A1
(en)
|
2012-08-02 |
2014-02-06 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
|
AU2013328301A1
(en)
|
2012-10-10 |
2015-05-28 |
Actelion Pharmaceuticals Ltd |
Orexin receptor antagonists which are [ortho bi (hetero-)aryl]-[2-(meta bi (hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives
|
|
WO2014130608A1
(en)
|
2013-02-22 |
2014-08-28 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
|
CN105051040A
(zh)
|
2013-03-12 |
2015-11-11 |
埃科特莱茵药品有限公司 |
作为食欲素受体拮抗剂的氮杂环丁烷酰胺衍生物
|
|
WO2014139388A1
(en)
|
2013-03-14 |
2014-09-18 |
Merck Sharp & Dohme Corp. |
Novel indole derivatives useful as anti-diabetic agents
|
|
JP2016514671A
(ja)
|
2013-03-15 |
2016-05-23 |
シナジー ファーマシューティカルズ インコーポレイテッド |
グアニル酸シクラーゼのアゴニストおよびその使用
|
|
JP2016514670A
(ja)
|
2013-03-15 |
2016-05-23 |
シナジー ファーマシューティカルズ インコーポレイテッド |
他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
|
|
EA201592263A1
(ru)
|
2013-06-05 |
2016-05-31 |
Синерджи Фармасьютикалз, Инк. |
Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования
|
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
|
UA119151C2
(uk)
|
2013-12-03 |
2019-05-10 |
Ідорсія Фармасьютікалз Лтд |
КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
|
|
JP6496733B2
(ja)
|
2013-12-03 |
2019-04-03 |
イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ |
（ｓ）−（２−（６−クロロ−７−メチル−１ｈ−ベンゾ［ｄ］イミダゾール−２−イル）−２−メチルピロリジン−１−イル）（５−メトキシ−２−（２ｈ−１，２，３−トリアゾール−２−イル）フェニル）メタノンの結晶形及びオレキシン受容体アンタゴニストとしてのその使用
|
|
KR102330133B1
(ko)
|
2013-12-04 |
2021-11-23 |
이도르시아 파마슈티컬스 리미티드 |
벤즈이미다졸-프롤린 유도체의 용도
|
|
TW201613902A
(en)
|
2014-08-13 |
2016-04-16 |
Eolas Therapeutics Inc |
Difluoropyrrolidines as orexin receptor modulators
|
|
LT3414241T
(lt)
|
2016-02-12 |
2022-08-25 |
Astrazeneca Ab |
Halogenu pakeisti piperidinai kaip oreksino receptoriaus moduliatoriai
|
|
WO2017194548A1
(en)
|
2016-05-10 |
2017-11-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases
|
|
US11072602B2
(en)
|
2016-12-06 |
2021-07-27 |
Merck Sharp & Dohme Corp. |
Antidiabetic heterocyclic compounds
|
|
EP3558298B1
(en)
|
2016-12-20 |
2026-03-11 |
Merck Sharp & Dohme LLC |
Antidiabetic spirochroman compounds
|
|
WO2020007964A1
(en)
|
2018-07-05 |
2020-01-09 |
Idorsia Pharmaceuticals Ltd |
2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives
|
|
WO2020099511A1
(en)
|
2018-11-14 |
2020-05-22 |
Idorsia Pharmaceuticals Ltd |
Benzimidazole-2-methyl-morpholine derivatives
|
|
AU2020286381C1
(en)
|
2019-06-04 |
2025-07-10 |
Hager Biosciences, Llc |
Imidazolo derivatives, compositions and methods as orexin antagonists
|
|
TW202400149A
(zh)
|
2022-05-13 |
2024-01-01 |
瑞士商愛杜西亞製藥有限公司 |
經噻唑并芳基-甲基取代之環狀肼-n-甲醯胺衍生物
|
|
GB202311281D0
(en)
*
|
2023-07-21 |
2023-09-06 |
Bial Portela & Ca Sa |
Orexin receptor antagonists
|
|
GB202311280D0
(en)
*
|
2023-07-21 |
2023-09-06 |
Bial Portela & Ca Sa |
Orexin receptor antagonists
|